Guardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET

Company Participants

Carrie Mendivil - IR

Helmy Eltoukhy - Co-CEO

AmirAli Talasaz - Co-CEO

Michael Bell - CFO

Conference Call Participants

Tejas Savant - Morgan Stanley

Dan Arias - Stifel

Mark Massaro - BTIG

Puneet Souda - Leerink Partners

Kyle Mikson - Canaccord Genuity

Jack Meehan - Nephron Research

Dan Brennan - TD Cowen

Patrick Donnelly - Citi

Derik De Bruin - Bank of America

Operator

Hello, everyone, and welcome to the Guardant Health Q3 2023 Earnings Call. My name is Thrisha, and I'll be your operator today. [Operator Instructions]

I will now hand you over to your host Carrie Mendivil, Investor Relations from Guardant Health. Please go ahead, Carrie.

Carrie Mendivil

Thank you. Earlier today Guardant Health released financial results for the quarter ended September 30, 2023. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO, and AmirAli Talasaz, Co-CEO and Mike Bell, Chief Financial Officer.

Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.

This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information regarding material risks and uncertainties as well as the reconciliation to the most directly comparable GAAP financial measures are available in the press release Guardant issued today as well as in our Form 10-K and other filings with the SEC. Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements whether of new information, future events or otherwise. The information in this conference call is accurate only as of the live broadcast.

With that, I'd like to turn the call over to Helmy.

Helmy Eltoukhy

Thanks, Carrie. Good afternoon and thank you for joining our third quarter 2023 earnings call.

I will start off our call today with our top-line results for the third quarter and then go into more detail on our progress in therapy selection and MRD. I will then turn the call over to AmirAli for an update on screening. And finally, Mike will provide a more detailed look at our financials and outlook for the remainder of 2023.

Starting on Slide 3. Guardant is a liquid biopsy leader in therapy selection with a strong pipeline of opportunities in MRD and screening. With our comprehensive suite of tests we are transforming patient lives across the continuum of care. In early September, we hosted our inaugural Investor Day where we shared our long-term vision for Guardant.